Results 91 to 100 of about 1,580 (184)

Efficacy and safety of cardiac myosin inhibitors for symptomatic hypertrophic cardiomyopathy: a meta-analysis of randomized controlled trials

Frontiers in Cardiovascular Medicine
IntroductionHypertrophic cardiomyopathy (HCM) is a common genetic heart disorder. It is characterized by left ventricular hypertrophy and impaired cardiac function, with forms categorized into obstructive (oHCM) and nonobstructive (nHCM).
Anas Abunada, Madiha Shah, Ateesh Kumar, Syeda Lamiya Mir, Dinesh Kumar, Saboor Ahmed, Muhammad Tanzeel, Vikash Kumar, Aashish Meghjiani, Muhammad Basit Ali Siddiqui, Govinda Khatri, Aneesh Rai, Fnu Deepak, Ayush Kumar   +13 more
doaj   +1 more source

Mavacamten for hypertrophic cardiomyopathy: effectiveness and value [PDF]

Journal of Managed Care & Specialty Pharmacy, 2022
Molly Beinfeld, Jason H Wasfy, Surrey Walton, Jyotirmoy Sarker, Emily Nhan, David M Rind, Steven D Pearson   +6 more
openaire   +1 more source

How effective is disopyramide in treating pediatric hypertrophic cardiomyopathy? State of the art and future directions

Monaldi Archives for Chest Disease
Pediatric hypertrophic cardiomyopathy (HCM) has a wide range of clinical manifestations. Left ventricular outflow tract obstruction (LVOTO) at rest is present in up to one-third of children with HCM, with a further 50-60% of symptomatic children ...
Karin Del Vecchio, Caterina Rizzardi, Alice Pozza, Francesco Prati, Luisa Ye, Alessia Fattoretto, Elena Reffo, Giovanni Di Salvo   +7 more
doaj   +1 more source

Echocardiographic Changes With Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy : Exploratory Insights From the ODYSSEY-HCM Trial

Symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM) lacks approved therapies. The ODYSSEY-HCM trial (A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy; NCT05582395), the largest to date in HCM patients, evaluating the ...
Gong Zhiqun, Sepp Róbert, Merkely Béla Péter, Fogarassy György, Lopes Renato D., Fronheiser Matthew, Nissen Steven E., Popovic Zoran B., Aronson Ron, Elliott Perry M., Abraham Theodore, Olivotto Iacopo, Jadam Shada, Owens Anjali, Geske Jeffrey B., Desai Milind Y., Florea Victoria, Garcia-Pavia Pablo, Maier Lars, Fernandes Fabio, Wolski Kathy, Okushi Yuichiro, Leva Arlene, Jaber Wael, Wang Qiuqing, et al., Kollaborációs szervezet: ODYSSEY-HCM Investigators   +26 more
core   +1 more source

An overview of the treatments for hypertrophic cardiomyopathy

Frontiers in Cardiovascular Medicine
Hypertrophic cardiomyopathy (HCM) is a very prevalent inherited disease with a wide global distribution and a prevalence rate of approximately 0.2% in the general population.
Wenna Xu, Fuyu Zhu, Yue Zhang, Peng Li, Peng Li, Yanhui Sheng, Yanhui Sheng   +6 more
doaj   +1 more source

Incidence and Outcomes of Atrial Fibrillation and Systolic Dysfunction in Patients Receiving Mavacamten for Obstructive Hypertrophic Cardiomyopathy: A Multicenter Study.

IMPORTANCE: Mavacamten is highly effective in treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM) and was approved for commercial use with a risk mitigation program (REMS) to monitor the impact on left ventricular systolic function (LVSD).
Owens, Anjali Tiku, Alsidawi, Said, Harper, Mariko, Carrick, Richard T, Abuzaid, Ahmed Sami, Prizand, Dmitry, Tajik, Jamil, Ravi, Sririam, Makkiya, Mohammed, Giudicessi, John R, Lewontin, Myra, Ho, Carolyn Y, Boyle, Thomas A, Wong, Timothy, Roldan, Paola, Kvapil, Jared, Tootill, Denise, Phelan, Dermot M, Lakdawala, Neal, Frankel, David S, Bilen, Ozlem, Shah, Hirak, Siqueira-Benzow, Alice, Choudhury, Lubna, Castrichini, Matteo, Zenker, Mark A, Berenbom, Loren, Lang, Melissa, Galazka, Patrycja, Massera, Daniele, Kanwal, Arjun, Liang, Lusha W, Nguyen, Olives, Mitter, Sumeet Singh, Flanagan, Michael, Sherrid, Mark, Frejat, Sumar, Saleh, Danish, Baghdadi, Sarah, Masri, Ahmad, Weiner, Shepard D, Ayers, Michael, Valenta, Isabela, Markowitz, Jeremy S, Jesurum, Jill, Hundal, Prabhjot, Madrazo, Jose, Adlestein, Elizabeth, Geske, Jeffrey B, Reza, Nosheen, Dellise, Nicole, Wiedrick, Jack   +51 more
core   +1 more source

Mavacamten in real‐life practice: Initial experience at a hypertrophic cardiomyopathy centre

ESC Heart Failure
Aims In clinical trials, mavacamten reduced left ventricular outflow tract obstruction (LVOTO) and improved symptoms in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
Zaid Abood, Muhammad Fuad Jan, Muddasir Ashraf, Stacie Kroboth, Heather Sanders, McKenzie Schweitzer, Amanda Misicka, Emily Ollerman, Arshad Jahangir, Patrycja Galazka, Abdul Jamil Tajik   +10 more
doaj   +1 more source

Forest plot showing a reduction in LVEF of Mavacamten compared to placebo at random effect.

Forest plot showing a reduction in LVEF of Mavacamten compared to placebo at random effect.
Kalgi Modi (7699319), Mansunderbir Singh (18405132), Anuj Thakre (18405138), Sahith Reddy Thotamgari (15947040), Rahul Vyas (18405123), Shubhika Jain (17719146), Viraj Panchal (18405126), Keerthish Jaisingh (18405135), Manush Sondhi (18405129)   +8 more
core   +1 more source

The Effect of Mavacamten on Echocardiographic Parameters, Cardiac Function and Biomarkers in Hypertrophic Cardiomyopathy Patients

Effect of Mavacamten on Echocardiographic Parameters, Cardiac Function and Biomarkers in Hypertrophic Cardiomyopathy ...
Ahmed K Awad
core   +1 more source

Myosin folding boosts solubility in cardiac muscle sarcomeres

JCI Insight
The polymerization of myosin molecules into thick filaments in muscle sarcomeres is essential for cardiac contractility, with the attenuation of interactions between the heads of myosin molecules within the filaments being proposed to result in ...
Colleen M. Kelly, Jody L. Martin, Michael J. Previs   +2 more
doaj   +1 more source